Compounds containing carbon-carbon linker as GPR120 agonists

A compound of Formula IA;

• wherein,
• Ring A is selected from the group consisting of a 3- to 10-membered cycloalkyl, a 5- to 12-membered heterocycloalkyl, a (C6-C10)aryl, and a 5- to 12-membered heteroaryl, wherein the heterocycloalkyl and the heteroaryl contain 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S;
• Ring B and Ring C are independently selected from a (C6-C10)aryl and a 5- to 12-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S;
• R is hydrogen or a (C1-C6)alkyl;
• R1, R2, and R3 at each occurrence are independently selected from the group consisting of hydrogen, a halogen, a (C1-C6)alkyl, a halo(C1-C6)alkyl, a 3- to 10-membered cycloalkyl, and a 5- to 12-membered heterocycloalkyl;
• and
• m, n and p are each an integer independently selected from 1, 2 and 3;
• wherein,
• the (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, and heteroaryl;
• the cycloalkyl is a 3- to 10-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heteroaryl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heterocycloalkyl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the halogen is selected from chlorine, bromine, iodine, and fluorine;
• or
• a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

A compound of Formula IB;

• Ring A is selected from the group consisting of a 3- to 10-membered cycloalkyl, a 5- to 12-membered heterocycloalkyl, a (C6-C10)aryl, and a 5- to 12-membered heteroaryl, wherein the heterocycloalkyl and the heteroaryl contain 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S;
• Ring B and Ring C are independently selected from the group consisting of (C6-C10)aryl, and a 5- to 12-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S;
• R is hydrogen or a (C1-C6)alkyl;
• R1, R2, and R3 at each occurrence are independently selected from the group consisting of hydrogen, a halogen, a (C1-C6)alkyl, a halo(C1-C6)alkyl, a 3- to 10-membered cycloalkyl, and a 5- to 12-membered heterocycloalkyl;
• R4 is independently selected from hydrogen or a (C1-C6)alkyl;
• R5 is independently selected from hydrogen, a halogen or a (C1-C6)alkyl;
• and
• m, n and p are each an integer independently selected from 1, 2 and 3;
• wherein,
• the (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, and heteroaryl;
• the cycloalkyl is a 3- to 10-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heteroaryl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heterocycloalkyl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the halogen is selected from chlorine, bromine, iodine, and fluorine;
• or
• a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

A compound of Formula IC;

• wherein,
• Ring A is selected from the group consisting of a 3- to 10-membered cycloalkyl, a 5- to 12-membered heterocycloalkyl, a (C6-C10)aryl, and a 5- to 12-membered heteroaryl, wherein the heterocycloalkyl and the heteroaryl contain 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S;
• Ring B and Ring C are independently selected from the group consisting of a (C6-C10)aryl and a 5- to 12-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S;
• R is hydrogen or a (C1-C6)alkyl;
• R1, R2, and R3 at each occurrence is independently selected from the group consisting of hydrogen, a halogen, a (C1-C6)alkyl, halo(C1-C6)alkyl, a 3- to 10-membered cycloalkyl, and a 5- to 12-membered heterocycloalkyl;
• R4 and R7 are independently selected from hydrogen or a (C1-C6)alkyl;
• R5 and R6 are independently selected from the group consisting of hydrogen, a halogen and a (C1-C6)alkyl;
• and
• m, n and p are each an integer independently selected from 1, 2 or 3;
• wherein,
• the (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocyclyl, and heteroaryl;
• the cycloalkyl is a 3- to 10-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocyclyl, heteroaryl, amino, and cyano;
• the heteroaryl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heterocycloalkyl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the halogen is selected from chlorine, bromine, iodine, and fluorine;
• or
• a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof.

A compound of Formula ID;

• wherein,
• Ring A is selected from the group consisting of a 3- to 10-membered cycloalkyl, 5- to 12-membered heterocycloalkyl, a (C6-C10)aryl, and a 5- to 12-membered heteroaryl, wherein the heterocycloalkyl and the heteroaryl contain 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S;
• Ring B and Ring C are independently selected from a (C6-C10)aryl or a 5- to 12-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S;
• X is selected from
• wherein represents a point of attachment;
• R is hydrogen or a (C1-C6)alkyl;
• R1, R2, and R3 at each occurrence are independently selected from the group consisting of hydrogen, a halogen, a (C1-C6)alkyl, a halo(C1-C6)alkyl, a 3- to 10-membered cycloalkyl, and a 5- to 12-membered heterocycloalkyl;
• R4 and R7 are independently selected from the group consisting of hydrogen and a (C1-C6)alkyl;
• R5 and R6 are independently selected from the group consisting of hydrogen, a halogen, and a (C1-C6)alkyl;
• and
• m, n and p are each integer independently selected from 1, 2 and 3;
• wherein,
• the (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, nitro, (C1-C6)alkyl, halo(C1-C6)alkyl, —O(C1-C6)alkyl, (C3-C8)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, and heteroaryl;
• the cycloalkyl is a 3- to 10-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heteroaryl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the heterocycloalkyl is a 5- to 12-membered ring, which is unsubstituted or substituted with one or more groups independently selected from the group consisting of (C1-C6)alkyl, halogen, hydroxy, —O—(C1-C6)alkyl, (C3-C10)cycloalkyl, (C6-C10)aryl, heterocycloalkyl, heteroaryl, amino, and cyano;
• the halogen is selected from chlorine, bromine, iodine, and fluorine;
• or
• a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof.